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Introduction
The excellent results of liver transplantation (LT) have led
to an increasing discrepancy between the number of
potential LT recipients and the available donation after
brain death (DBD) liver donors. Alternative sources of
liver grafts have been developed to overcome this organ
shortage somehow, including living liver donors, split liver
grafts, extended criteria DBD donors, and donation after
cardiac death (DCD) donors [1,2]. Contrary to DBD
donors, in DCD donation, death is diagnosed on the basis
of cardiovascular criteria, after cessation of the blood flow
during a sufficient time allowing to determine cardiovas-
cular death [3]. DCD donation imposes thus an additional
warm ischemic injury prior to organ preservation by cool-
ing and flushing. This supplementary insult may increase
the rate of graft failure because of primary non-function
(PNF) and ischemic type biliary lesions (ITBL) [4].
In 1995, the Maastricht conference defined four catego-
ries of DCD donors [5]. Practically, in LT, DCD donors
may be classified as uncontrolled or controlled. In uncon-
trolled DCD donors, the cessation of cardiopulmonary
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Abstract
The Belgian experience with donation after cardiac death (DCD) liver trans-
plantation (LT) was retrospectively reviewed, particularly evaluating patient
and graft survivals, and biliary complications. From 2003 to 2007, 58 DCD-LT
were performed in Belgium. Mean procurement total warm ischemia time was
25 ± 2 min (mean ± SEM). Mean cold ischemia time was 451 ± 18 min. Mean
follow-up was 23 ± 2.2 months. Post-transplant peak aspartate aminotransmin-
ases was 2241 ± 338 UI/l. Patient survivals at 1 month, 1 and 3 years, were
91.3%, 83.3% and 66.9% respectively. Graft survivals at 1 month, 1 and
3 years, were 84.4%, 72.4% and 48.8% respectively. Two patients (3.4%) devel-
oped primary nonfunction. Regarding the biliary complications, seven grafts
(12%) were lost because of intrahepatic cholangiopathy, and 12 other patients
(20.6%) developed bile duct stenoses requiring endoscopic and/or surgical
management. The rate of symptomatic ischemic biliary lesions for grafts surviv-
ing more than 3 months was 38% (19/50). Although DCD organ donors may
be a source of viable liver grafts, results were inferior to those obtained with
donation after brain death LT in this series. Prognostic criteria have to be
developed to improve results of DCD-LT.
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function is an unplanned event that may occur outside
the hospital (Maastricht category I) or within the hospital
(Maastricht category II). In controlled DCD donors (Ma-
astricht category III), cessation of cardiovascular activity
may be planned in a patient with severe and irreversible
cerebral lesions in whom intensive care is deemed futile
by the medical team in charge, independently of any
organ donation. When medical decision of care with-
drawing is confirmed to the patient’s next of kin, the pos-
sibility of DCD donation and the patient’s willingness for
after death organ donation may be discussed. DCD pro-
cedure may be planned with donor extubation either in
the intensive care unit (ICU) or in the operating room.
In this controlled DCD, procurement warm ischemic
injury may be minimized by the presence of the organ
procurement surgical team ready for rapid after death
organ retrieval. The Maastricht category IV DCD donors
constitute a small group of DBD organ donors who
developed unexpected cardiac arrest just before or during
organ procurement.
With the increasing donor organ shortage, the use of
DCD liver grafts has been increasingly reported. Programs
of Maastricht category III DCD-LT have been developed
in the United-States as well as in Western Europe and
some centers even developed DCD-LT programs using
Maastricht category II livers [6]. Good results of Maas-
tricht category III DCD-LT, comparable to the results of
DBD-LT, have been reported [7–10]. However, most cen-
ters, as well as the reports from the United Network for
Organ Sharing (UNOS) network registry, demonstrated
an increased risk for liver graft failure [11–18]. After the
initial and successful development of DCD renal trans-
plantation in the Netherlands and Belgium, programs of
liver, lung or pancreatic islet transplantation were initi-
ated [19–21]. The aim of this retrospective study was to
evaluate the results of the Belgian multicenter experience
in DCD-LT, in terms of patient and graft survivals, and
of ITBL. The authors also intended to determine the
donors’ characteristics and the transplant variables that
may be linked to the results of DCD-LT.
Patients and methods
This study was a retrospective review of the Belgian expe-
rience with DCD-LT during the period from 2003 to
December 2007, and is an extension of a preliminary
report on the 2003–2005 period [19]. DCD donation has
been initiated in all Belgian transplant centers after
approval by the different institutional committees, and
the Belgian National Council of Physicians [21]. The Bel-
gian LT community is composed of six active transplant
centers sharing a common pool of organ donors and a
national waiting list with a patient-oriented liver graft
allocation performed by the Eurotransplant organization.
These centers are responsible for the liver graft procure-
ments within their regional area. The first Belgian DCD-
LT were performed in 2003 [19], and all six Belgian LT
centers had active DCD-LT program by 2008. A DCD-LT
registry was created by the Belgian Liver Intestinal Com-
mittee, a section of the Belgian Transplant Society. Com-
plete follow-up was obtained up to December 31, 2007,
in a retrospective manner. Mean follow-up was
23 ± 2.2 months (range, 1–60 months). No patient was
lost to follow-up.
From 2003 to December 2007, 58 DCD-LT were per-
formed in Belgium, representing 4.7% of the 1239 Belgian
LT activity in the same period. Fifty-six were from Maas-
tricht category III donors and two from category IV. No
category II DCD-LT was performed despite active cate-
gory II DCD procurement programs in some Belgian cen-
ters. For category III donors, withdrawal of life support
and extubation were performed by a nontransplant physi-
cian in the operative room in all cases. Intravenous hepa-
rin was given in most cases before cessation of
circulation. Organ recovery started 2–5 min after declara-
tion of death, by cannulation of the femoral vessels or by
rapid midline laparotomy and sternomy with caval and
aortic cannulation. Once the cold flush with university of
Wisconsin (UW) or histidine–tryptophan–ketoglutarate
(HTK) solutions was initiated, the aorta was cross-
clamped in the chest just above the diaphragm, whereas
the abdominal and thoracic cavities were filled with iced
fluid for topical cooling. After completion of the aortic
flush, the organs were removed and stored in a standard
manner until transplantation.
Donation after cardiac death liver grafts were consid-
ered as marginal grafts, and were allocated in a center-
oriented manner to shorten cold ischemia time (CIT).
The recipients were chosen according to the urgent need
for transplantation and his (her) chances to receive a liver
graft in a timely manner according to the regular patient-
oriented rules, and this included patients with extended
criteria hepatocarcinoma. If no adequate candidate was
available, the DCD liver graft was offered to other centers
in Belgium and the Netherlands, two Eurotransplant
countries allowing DCD procurement.
In all DCD donors, age, gender, cause of brain damage,
terminal blood sodium level, terminal liver function tests,
need of vasopressors, length of the ICU stay, body mass
index (BMI), last 24-h diuresis, past cardiopulmonary
resuscitation, were collected. In the recipients, age, gen-
der, LT indication, status 1 or hyper urgent (HU) status,
last laboratory model for end-stage liver disease (MELD)
score before transplantation, were recorded. The use of
heparin in the donor, the type of preservation solution
(UW or HTK), and the exchange between centers that
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transplanted but not procured DCD liver grafts, were also
noted.
Donor total warm ischemia time (DTWIT) was defined
as the time between discontinuation of mechanical venti-
lation and initiation of aortic perfusion with the cold
preservation solution [22]. DTWIT was divided into two
separate phases, the time of life-support withdrawal to
cardiac arrest (withdrawal phase), and the time between
cardiac arrest to aortic cannulation (acirculatory phase),
as proposed [3]. CIT was defined as the time from aortic
cold perfusion until reperfusion of the liver graft in the
recipient. Procurement time was defined as the time from
aortic cold perfusion to placement of the liver graft in
iced preservation fluid. Suture time was defined as the
time from removing the liver graft from the iced preser-
vation fluid to revascularization of the graft.
Primary endpoints of this retrospective study were graft
and patient survivals. Graft survival was defined as time
from LT to graft loss and/or patient death. Patient sur-
vival was considered from first transplantation to patient
death. To estimate better the risks of DCD-LT, we calcu-
lated graft and patient survivals censored for recipient
death unrelated to the quality of the graft (malignant
tumor, accident), as a secondary endpoint. Secondary
endpoints were also early death (<3 months post-OLT),
first week peaks of transaminases and total bilirubin,
occurrence of PNF, hepatic artery thrombosis (HAT),
length of the ICU and hospital stays, and need for re-
transplantation. The overall rate of symptomatic intra-
and extra-hepatic biliary complications requiring invasive
(endoscopy, surgical hepaticojejunostomy or retransplan-
tation) management, was also studied, excluding grafts
lost within 3 months from causes unrelated to biliary
problems.
Data are presented as means ± standard error of the
mean (SEM). Means were compared with Student t-test,
and proportions were compared with Fischer’s or chi-
square test, when appropriate. Survival rates were esti-
mated with the Kaplan–Meier method. Linear regression
was used to link the different times of the transplant pro-
cedures, to the level of peak transaminases and total bili-
rubin. A value of P < 0.05 was considered significant.
Data were analyzed using the instat 3.0b and prism 5




The characteristics of the DCD donors are presented in
Table 1. Donors were mostly men, and their mean age
was 44.6 ± 1.9 years. Trauma was the main cause of irre-
versible brain damage leading to withdrawal of medical
support; four patients who were waiting medical-assisted
death or euthanasia according to the Belgian law,
requested after-death organ procurement. Mean ICU stay
before withdrawal was 4.8 ± 0.5 days. Liver tests were at
the upper limit of normal values.
Recipient baseline characteristics
Recipients’ mean age was 54.9 ± 1.5 years (range,
10–70 years). Indication for LT was end-stage cirrhotic
liver disease in 26 patients (viral: 8, alcohol-related: 12,
primary biliary cirrhosis: 2, others: 4), hepatocellular can-
cer in 22 patients (cirrhotic livers: 20, noncirrhotic livers:
2), and miscellaneous in five cases (primary sclerosing
cholangitis: 2, familial amyloid polyneuropathy: 1,
neurendocrine liver metastases: 1, biliary atresia: 1). Addi-
tionally, in five cases, DCD LT was performed for HU
patients (Eurotransplant equivalent to UNOS status 1a)
for fulminant hepatic failure (2), liver failure after resec-
tion for Klatskin tumor (1) and urgent retransplantation
after failed first transplantation (2). Mean lab MELD
score at transplantation was 15.4 ± 1 (range, 6–37).
DCD procurement and LT characteristics
The characteristics of the DCD procurements and LT are
presented in Table 2. Heparin was administrated in more
than 80% of the DCD donors before cardiac arrest. HTK
preservation solution was used in 65% of the cases.
Thirty-eight DCD grafts were allocated within the procur-
ing center. Twenty DCD liver grafts were exchanged
between centers; 15 were shipped from other Belgian cen-
ters (national allocation) and five from the Netherlands
Table 1. Baseline donors’ characteristics.
Data Range
Age (years) 44.6 ± 1.9 13–71
Female (%) 32.7
CPR (%) 25.8





BMI (kg/m2) 24.5 ± 0.5 18–38
Intensive care stay (days) 4.8 ± 0.5 0–19
Urinary output (ml/day) 3002 ± 266 980–8450
Pressors (%) 44.8
Na (mmol/l) 142.3 ± 0.8 129–164
Total bilirubin (mg/dl) 0.53 ± 0.04 0.11–1.3
AST (U/l) 50.5 ± 5.7 10–300
GGT (U/l) 59.8 ± 12.1 3–606
CPR, cardiopulmonary resuscitation; BMI, body mass index; AST,
aspartate aminotransferase; GGT, gamma glutamil transferase.
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(international allocation). Mean DTWIT was 25.18 ±
2.2 min, and mean CIT was 451 ± 18 min.
Primary end-points
Overall graft and patient survival rates are presented in
Fig. 1a. One-month-, 1-year- and 3-year-patient survivals
were 91.3%, 83.3% and 66.9%, respectively. One year-
and 3-year-graft survivals were 84.4%, 72.4% and 48.8%,
respectively. Causes of early death (<3 months) were per-
operative cardiac failure in two cases, PNF in one case,
acute respiratory distress syndrome in one case, multiple
organ failure in one case, and liver insufficiency with
HAT in one case. Eight other patients died later, one
from intractable biliary sepsis while waiting retransplanta-
tion, five from cancer (melanoma: 1, lymphoma: 1, donor
transmitted sarcoma: 1, hepatocarcinoma recurrence: 2)
and two from violent death (car accident and suicide).
Eight patients underwent retransplantation, two urgently
for PNF (n = 1) and HAT (n = 1), and six for intractable
biliary stenoses, one at month six post-transplant after
HAT surgically revascularized at post-transplant day 7.
One of the patients who underwent late retransplantation,
died from lymphoma at postoperative month 7. In total,
21 DCD liver grafts were lost for reasons of retransplanta-
tion or death at follow-up (Table 3).
In univariate analysis, the relationship between charac-
teristics of the donors, the recipients and the transplant
procedures, and global graft and patient survivals as pri-
mary endpoints, showed a tendency to a higher risk of
graft and patient loss in case of CIT longer than 6 h, and
in case of withdrawal phase of the procurement exceeding
15 min (Table 4). There was a tendency to a lower risk of
graft failure if DTWIT was inferior to 20 min (Table 4).
Postoperative evolution and secondary end-points
Six patients (10.3%) who certainly died of causes unre-
lated to the graft quality (malignant tumor and accident)
and who did not undergo retransplantation, were
excluded for calculation of censored-patient and graft sur-
vival (Fig. 1b). One- and 3-year-censored patient survivals





Graft origin L/N/I (n) 38/15/5
DTWIT (min) 25.18 ± 2.2 10–109
Withdrawal phase (min) 14.75 ± 2.09 4–98
Acirculatory phase (min) 10.6 ± 0.84 4–38
Procurement time (min) 42.5 ± 3.1 15–92
CIT (min) 451 ± 18 148–770
Suture time (min) 50 ± 2.3 25–135
DCD, donation after cardiac death; DTWIT, donor total warm ische-
mia time; CIT, cold ischemia time; HTK, histidine–tryptophan–ketoglu-
tarate solution; UW, University of Wisconsin solution; Graft origin: L,
local; N, national; I, international.
(a)
(b)
Figure 1 Patient and graft survivals according to the Kaplan–Meier
curves. (a) Global survival curves. (b) Survival curves censored for
patients who died of cancer or trauma.
Table 3. Causes of the 21 losses of DCD hepatic grafts during fol-
low-up.
Causes of graft loss n Outcome
Link to DCD
donation
PNF 2 1 death, 1 reTx Probable
Operative death 2 2 deaths Possible
Hepatic artery thrombosis 2 1 death, 1 reTx Possible
ARDS, MOF 2 2 deaths Possible
Diffuses intrahepatic stenoses 7 1 death, 6 reTx* Highly probable
Unrelated death 7 7 deaths None
DCD, donation after cardiac death; PNF, primary non function; re Tx,
retransplantation; ARDS, acute respiratory distress syndrome; MOF,
multiple organ failure.
*One patient underwent retransplantation for intrahepatic stenoses
6 months after successful surgical hepatic artery revascularization.
One patient died of lymphoma 6 months after retransplantation for
intrahepatic bile duct stenoses).
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were 87.5%; 1- and 3-year-censored graft survivals were
76.6% and 66.8%, respectively.
Postoperative mean peak AST was 2242 IU/l ± 338
(range, 34–10 505 IU/l) and mean peak total bilirubin
was 6.76 ± 0.93 mg/dL (range, 0.77–29.6 mg/dL). Consid-
ering early post-LT death, results were significantly lower
in urgent LT (Table 5). There was a trend for a correla-
tion between the length of CIT and the post-transplant
peak AST (slope: 4.63; r: 0.253; P = 0.06). No other sig-
nificant correlation was demonstrated between DTWIT,
CIT, DTWIT added to CIT, procurement time and suture
time and post-transplant peaks of AST or bilirubin. For
patients surviving the first month, mean ICU and hospital
stays were 6.98 ± 1.22 days (range, 1–46 days) and
33.81 ± 5.06 days (range, 10–213 days), respectively.
In addition to the seven DCD (12%) liver grafts lost
for reasons of diffuse intrahepatic stenoses (one death
and six retransplantations), 12 (20%) other patients
developed ITBL requiring endoscopic and/or surgical
management. Censoring the eight DCD graft losses within
the first 3 months (six early deaths and two early retrans-
plantations for PNF and HAT), the overall rate of symp-
tomatic bile duct lesions was 38% (19/50). We could not
identify clear risk factors for ITBL (Table 5). Unexpect-
edly, donor age over 50 years and gamma glutamyl trans-
ferase superior to 50 U/l were significantly associated with
a decreased risk of bile duct problems, but this result is
probably not medically relevant.
Discussion
This retrospective study on the Belgian experience in
DCD-LT shows that controlled Maastricht category III
DCD donors constitute a potential source of liver grafts
that may partially help fill the gap between the needs for
LT and the overall DBD liver graft pool. However, this




P Risk ratio 95% CI P Risk ratio 95% CI
Donor
Donor age <50 years 0.37 0.864 0.652–1.145 0.41 1.227 0.815–1.847
ICU <5 days 1 1.037 0.376–2.853 0.76 0.91 0.637–1.31
Cause of death 0.5 0.13
BMI<25 kg/m2 0.75 1.218 0.4383–3.384 1 0.986 0.677–1.437
Cardiac arrest (yes versus no) 0.32 0.478 0.12–1.894 0.21 0.44 0.14–1.386
Donor inotropes (yes versus no) 1 1.031 0.427–2.488 1 0.932 0.509–1.708
Donor AST <50 U/l 0.35 1.786 0.563–5.659 0.77 1.101 0.768–1.578
Donor GGT <50 U/l 1 1.063 0.386–2.921 0.55 1.143 0.819–1.594
Transplantation
Graft allocation (L/N/I) 0.12 0.24
Heparin (yes versus no) 0.1 0.383 0.163–0.899 0.14 0.798 0.596–1.069
DTWIT <20 min 0.48 0.589 0.189–1.833 0.06 0.506 0.233–1.097
DTWIT <30 min 0.39 0.585 0.192–1.783 0.43 0.875 0.639–1.197
Withdrawal phase <10 min 0.5 0.63 0.245–1.623 0.76 0.875 0.427–1.793
Withdrawal phase <15 min 0.02* 0.725 0.502–1.048 1 0.959 0.67–1.371
Acirculatory phase <10 min 1 0.889 0.286–2.757 0.14 0.685 0.423–1.108
Acirculatory phase <15 min 0.5 0.706 0.276–1.803 0.16 0.845 0.67–1.067
Flush solution (HTK/UW) 0.1 0.408 0.177–0.936 0.47 0.881 0.671–1.155
Procurement time <45 min 1 1.032 0.392–2.712 0.37 0.761 0.45–1.289
CIT <6 h 0.08 0.288 0.067–1.24 0.04* 0.463 0.207–1.035
CIT <10 h 1 1.347 0.208–8.685 1 1.003 0.829–1.214
Suture time <60 min 0.7 0.814 0.268–2.471 1 1.039 0.809–1.333
Recipient
Age recipient <50 years 0.71 1.385 0.518–3.696 0.35 1.636 0.662–4.04
MELD <15 0.32 1.877 0.57–6.17 0.54 1.184 0.758–1.849
HU 0.07 3.18 1.283–7.884 0.34 2.571 0.466–14.171
Center 0.9 0.46
ICU, intensive care unit; BMI, body mass index; AST, aspartate aminotransferase; GGT, gamma glutamil transferase; L, local; N, national; I, interna-
tional; DTWIT, donor total warm ischemia time; CIT, cold ischemia time; MELD, model for end-stage liver disease score; HU, high urgency status;
HTK, histidine–tryptophan–ketoglutarate solution; UW, University of Wisconsin solution. *P < 0.05.
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series also demonstrates an overall inferior DCD liver
graft survival (49% at 3 years). Moreover, the biliary
complications rate of grafts that did not fail within the
first 3-month post-LT was already 38% in this series after
a relatively short follow-up of 23 months. These results
are in accordance with the higher risk of biliary complica-
tions and graft loss in DCD-LT, as reported in earlier
studies [23].
Most of the Belgian DCD liver grafts originated from
Maastricht category III DCD donors. Despite active cate-
gory II DCD kidney procurement programs in some Bel-
gian centers, such donors were not used for liver graft
donation within the study period. In Maastricht category
III donation, cessation of life support is a planned event
in which the period between cessation of ventilation and
cardiac arrest and aortic flushing, might be easily moni-
tored. Moreover, the presence of the procurement team
at the time of life support withdrawal, allows to limit
donation DTWIT to a minimum. For these reasons,
Maastricht category III DCD donation has also been
called ‘controlled’ DCD. On the contrary, in uncontrolled
DCD donors, the cessation of cardiopulmonary function
is an unplanned event that may occur outside the hospital
(Maastricht category I) or within the hospital (Maastricht
category II). The procurement DTWIT is therefore longer
and difficult to define in uncontrolled DCD, increasing
the risks for ischemic failure of the graft. The results of
this study will certainly not favor the extension of con-
trolled DCD-LT to an uncontrolled DCD-LT activity in
the next years in Belgium.
A particularity of DCD donation in Belgium consists of
the possibility of after death procurement in individuals
who required euthanasia as allowed by the Belgian law
[24]. Belgium was the second country in the world after
the Netherlands to legalize medically assisted death or
euthanasia under very strict conditions [24]. Four
Table 5. Univariate analysis comparing the secondary end-points and different factors linked to the donor, the recipient or the transplantation
procedure.
Factors
Early death Censored graft failure Biliary complications
P Risk ratio 95% P Risk ratio 95% P Risk ratio 95%
Donor
Donor age <50 years 0.225 1.507 1.025–2.217 0.533 1.209 0.8–1.826 0.018* 1.842 1.132–2.997
ICU <5 days 0.683 0.857 0.439–1.671 0.311 0.761 0.469–1.237 0.521 1.145 0.817–1.604
Causes of death 0.684 0.365 0.294
BMI<25 kg/m2 0.407 1.325 0.92–1.907 0.757 1.084 0.731–1.607 0.362 1.257 0.836–1.889
Cardiac arrest (yes versus no) 0.178 NA NA 0.086 0.224 0.032–1.559 0.11 0.381 0.123–1.176
Donor inotrope (Yes versus No) 0.69 1.59 0.39–6.47 0.525 1.393 0.711–2.725 0.386 0.704 0.324–1.53
Donor AST <50 U/l 1 1.218 0.259–5.714 0.757 0.942 0.607–1.463 1 1.068 0.723–1.578
Donor GGT <50 U/l 0.661 2.55 0.331–19.612 0.189 1.316 0.969–1.788 0.025* 1.599 1.103–2.318
Transplantation
Type of allocation (L, N, I) 0.567 0.565 0.55
Heparin (Yes versus No) 0.338 0.51 0.114–2.27 0.690 0.934 0.69–1.264 0.695 0.915 0.696–1.205
DTWIT <20 min 0.661 0.615 0.112–3.373 0.164 0.521 0.195–1.395 1 0.96 0.536–1.717
DTWIT <30 min 1 0.952 0.118–7.627 0.646 0.937 0.67–1.31 0.679 0.933 0.695–1.253
Withdrawal phase <10 min 0.645 0.54 0.12–2.436 0.713 0.74 0.276–1.985 0.754 1.145 0.564–2.323
Withdrawal phase <15 min 0.115 0.235 0.054–1.025 0.669 0.86 0.526–1.406 0.295 0.789 0.512–1.216
Acirculatory phase <10 min 0.625 0.444 0.049–3.979 0.184 0.655 0.353–1.215 0.365 0.789 0.511–1.217
Acirculatory phase <15 min 1 0.973 0.111–8.505 0.328 0.909 0.711–1.163 1 1.014 0.873–1.178
Flush solution (HTK/UW) 0.591 0.52 0.117–2.316 1 1.048 0.811–1.352 0.451 1.128 0.886–1.436
Procurement time <45 min 0.672 0.666 0.149–2.98 0.177 0.625 0.308–1.265 0.746 0.919 0.577–1.464
CIT <6 h 0.358 0.288 0.034–2.422 0.513 0.682 0.289–1.608 0.555 1.291 0.739–2.254
CIT<10 h 1 NA NA 0.096 1.364 1.143–1.626 1 1.031 0.828–1.283
Suture time <60 min 1 1.209 0.147–9.897 1 1.019 0.763–1.36 0.235 0.821 0.611–1.105
Recipient
Age recipient <50 years 0.18 0.385 0.098–1.507 0.267 1.964 0.765–5.038 0.487 1.526 0.509–4.57
MELD <15 0.375 0.444 0.082–2.402 0.312 0.711 0.355–1.422 0.733 1.116 0.716–1.738
HU 0.01* 7.95 2.434–25.964 0.094 4.5 0.829–24.424 1 1.4 0.092–21.092
Center 0.07 0.015* 0.052*
ICU, intensive care unit; BMI, body mass index; AST, aspartate aminotransferase; GGT, gamma glutamil transferase; L, local; N, national; I, interna-
tional; DTWIT, donor warm ischemia time; CIT, cold ischemia time; MELD, model for end-stage liver disease score; HU, high urgency status; HTK,
histidine–tryptophan–ketoglutarate solution; UW, University of Wisconsin solution. *P < 0.05.
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patients who suffered from severe neurological diseases
and who were granted euthanasia required that procure-
ment of their organs should be performed after their
death. These procurements were allowed by the ethical
committees of the institution where the euthanasia proce-
dures were performed [25]. As these procedures included
a planned and medically controlled cardiopulmonary
arrest, they were naturally classified in the Maastricht cat-
egory III donation category.
In this series, we, as others [3,12,17,18,22,26–30], used
the definition of DTWIT as the interval between discon-
tinuation of donor mechanical ventilation to the aortic
perfusion with the cold preservation solution. DTWIT
may be divided into two separate phases, the time from
life-support withdrawal to cardiac arrest (withdrawal
phase), and the time from cardiac arrest to aortic cannu-
lation (acirculatory phase), as described by the 2006
American consensus report [3]. This definition of the
DCD procurement DTWIT is imperfect, but has the mer-
its to be simple and useful for comparison of studies.
During the circulatory arrest phase, warm ischemia is
complete as no cardiac flow and pulmonary function are
observed. During the withdrawal phase, warm ischemia is
only partial as this period is marked by varying periods
of hypotension and hypoxia before the cessation of all
cardiopulmonary function. Some authors used alternative
definitions of warm ischemia, e.g. mean or systolic arte-
rial pressure lower than 60 mmHg [22], 50 mmHg [16]
or 35 mmHg [31] and/or oxygenation saturation <70%
[7,32], 60% [16] or 35% [31], or mean arterial pressure
<30 mmHg and/or oxygen saturation <25% [17,31].
Clearly, there is a need for a consensus in this matter.
Practically, we consider that these data are very often
impossible to trace back precisely, especially in a retro-
spective multicenter study. Moreover, oxygen saturation
is often difficult to monitor noninvasively during DCD
donation once its value is below 80%, as pulse oxymeters
are not calibrated to low oxygen saturation and premor-
tem vasoconstriction does not always allow reliable
recordings.
This multicenter Belgian study showed overall 3-year
patient and graft survival rate of 66.9% and 48.8%,
respectively. This series was comparable to the other
reports on DCD-LT in literature in terms of DTWIT and
CIT [7,17,18,23,31,32]. One-year graft and patient surviv-
als were quite equivalent to other reported series. How-
ever, our 3-year results are worse than previously
reported, a feature which may be related to the particular
high rate of deaths caused by events unrelated to DCD
procurement such accident and cancer, and by the high
rate of retransplantation.
Overall, 38% of DCD grafts surviving 3 months devel-
oped ITBL, a rate of biliary complications higher than
usually expected in DBD-LT. This is probably explained
by the addition of donation DTWIT to CIT. A with-
drawal phase of more than 15 min was significantly
related to an increased risk of post-transplant death, and
a CIT of more than 6 h was linked to graft failure. These
results are consistent with data in the literature, indicat-
ing that in DCD-LT, both warm and CIT must be lim-
ited to a minimum. We were not able to indentify in
this series other compromising factors for DCD-LT
results. This is probably linked to the fact that LT
results depend on multiple donor and recipient variables
and that a higher case load is necessary to find out
compromising factors.
In this multicenter Belgian experience, 1- and 3-year-
graft survivals, censored for accidental or cancerous
patient’s death, were 87.5% and 66.8%, respectively.
These results mean that even in this preliminary experi-
ence, two-third of the DCD liver grafts may provide a
chance to receive a life-saving graft. This is an important
message in the current era of organ donor shortage and
too high rate of death on the waiting lists. Better knowl-
edge of the risks of DCD-LT failure, and particularly a
limitation of the warm and cold ischemia, may offer bet-
ter results in the future.
In recent reports, it was suggested that DCD donor age
of more than 40 or 50 years and ICU stay of more than
5 days, may be risk factors for post-transplant DCD-LT
failure [17]. Our results, as others [31], did not support
these findings. Similarly, we did not experience an early
increased graft failure from viral recurrence in hepatitis C
virus positive patients (data not showed), as described by
others [30].
In conclusion, the multicenter Belgian experience with
DCD-LT confirmed that DCD liver grafts carry an
increased risk of graft failure. Overall results were inferior
to what should be expected in the modern era of LT, with
one-half of the grafts lost at 3 years. Procurement DTWIT
beneath 30 min and CIT beneath 6 h seem to be related
to better outcome. Further improvements are needed to
allow wider and safer use of DCD liver grafts. For the
time being, these grafts should be carefully used in
informed patients, in whom current allocation scheme
does not provide sufficient chances to be transplanted
with a regular DBD graft in a timely manner.
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